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The 12/15-lipoxygenase (12/15-LO) and cyclooxygenase-2
(COX-2) pathways of arachidonate metabolism have been
implicated in the pathogenesis of diabetic nephropathy (DN).
In this study, we evaluated whether there is an interplay
between 12/15-LO and COX-2 pathways in mesangial cells
(MC). We utilized MC, microdissected glomeruli and renal
cortical tissues. Transfections with cDNAs or short hairpin
RNAs (shRNAs) were performed to overexpress or
knockdown 12/15-LO and COX-2, respectively. Reverse
transcription-polymerase chain reactions and Western
blotting were used for evaluating mRNA and protein
expression, respectively. We observed that the expression
of both 12/15-LO and COX-2 were increased in high
glucose stimulated rat MC relative to normal glucose,
and also in cortical tissues from diabetic db/db and
streptozotocin-injected mice relative to corresponding
control mice. Treatment of rat MC with the 12/15-LO product,
12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE), significantly
increased COX-2 expression as well as levels of the COX-2
product, prostaglandin E2 (PGE2). Interestingly, treatment of
rat MC with PGE2 led to a reciprocal increase in 12/15-LO
expression as well as levels of 12(S)-HETE. The 12/15-LO
shRNA could significantly attenuate COX-2 protein
expression and vice versa. Furthermore, COX-2 expression
levels were lower in MC and glomeruli from 12/15-LO
knockout mice relative to control. Conversely, mouse MC
stably overexpressing 12/15-LO had greater levels of COX-2
expression relative to mock-transfected cells. These new
results indicate for the first time that 12/15-LO and COX-2
pathways can cross-talk and activate each other in MC. These
novel interactions may amplify their effects on the
progression of DN.
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Arachidonic acid can be metabolized by at least three
different pathways: the lipoxygenase (LO) pathway to LO
products such as hydroxyeicosatetraenoic acids (HETEs) and
leukotrienes; the cyclooxygenase (COX) pathway to prosta-
glandins (PGs) such as PGD2, PGE2, prostacyclin, PGF2a, and
thromboxane A2; and the cytochrome P-450 epoxygenase
pathway to epoxides and other products.1–7 LOs are classified
as 5-, 8-, 12-, and 15-LO based on the carbon atom of
arachidonic acid at which oxygen is inserted.2,3 12-LO
activation can lead to the formation of oxidized lipids such
as 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE).2 Hu-
man and rabbit 15-LO as well as the leukocyte-type 12-LO
have high homology and are classified as 12/15-LO as they
can form both 12(S)-HETE and 15(S)-HETE from arachi-
donic acid.8 COX, also known as PGH synthase, is a
membrane-bound, bifunctional enzyme that catalyzes the
conversion of arachidonic acid to PGG2 by its COX activity,
and PGG2 to PGH2 by peroxidase activity.
4–7 There are two
major isoforms of COX, COX-1, and COX-2.4,5 COX-1 is
constitutively expressed in most tissues. In contrast, COX-2
operates as an inducible enzyme with low or undetectable
levels in most tissues.4,5
Factors relevant to the pathogenesis of diabetic nephro-
pathy (DN) such as high glucose and angiotensin II can
induce leukocyte-type 12/15-LO activity and expression in
rat mesangial cells (MC).8–10 Furthermore, in vivo expression
of the matrix protein fibronectin in the diabetic rat glomeruli
was associated with increased glomerular 12/15-LO expres-
sion.8 12(S)-HETE could directly induce cellular hypertrophy
and expression of the extracellular matrix protein, fibronec-
tin, in rat MC or vascular smooth muscle cells with similar
potency as angiotensin II.10–13 Furthermore, the growth-
promoting and matrix inducing effects of angiotensin II in
MC were blocked by pharmacological 12-LO inhibitors as
well as a novel 12-LO ribozyme.10
Previous studies demonstrated that urinary and glome-
rular prostaglandin production and COX-2 expression were
increased in experimental models of diabetes.14–18 PGs have
been implicated as mediators of the alterations in renal
hemodynamics in early diabetes, and of increased MC
proliferation and matrix accumulation.17–19 Glomerular
hyperfiltration is a characteristic finding of early diabetes in
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both humans and animal models of diabetes and may play
a major role in the pathogenesis of DN.4,17 The mechanisms
that mediate an increase in glomerular filtration rate are
not well identified, but the vascular reactivity of the
renal glomerular afferent arterioles has been shown to be
controlled, at least in part, by the release of endogenously
synthesized PGs, such as those derived from COX-2, allowing
autoregulation of glomerular capillary pressure.17,18
Several studies have demonstrated that 12/15-LO and
COX-2 mRNA and protein are increased in high glucose
(HG)-stimulated MC and in patients with diabetes and also
in experimental DN.8,14,16,18–24 Specific COX-2 inhibitors
could decrease proteinuria and retard progressive renal injury
in rats.22,25 In a rat model of DN, a 12-LO inhibitor showed
transient relationship between 12/15-LO suppression and
reduction in proteinuria.26 These studies indicate that 12/15-
LO and COX-2 play important roles in the pathogenesis of
progressive renal diseases such as DN. COX-2 is also an
important physiological mediator of kidney function.27–29
However, the relationship between 12/15-LO and COX-2 in
MC or DN is not very clear. The goal of this study was to
clarify whether these two pathways can cross-talk in MC. We
noted for the first time that inflammatory and growth-
promoting lipid products of these pathways could cross-
regulate each other.
RESULTS
12/15-LO and COX-2 are increased in HG–stimulated MCs and
cortex from diabetic animal
We first observed that rat MC (RMC) cultured in medium
containing HG (25 mM) for 24 h had greater levels of 12/15-
LO and COX-2 protein relative to those cultured in normal
glucose (NG) (5.5 mM) (Figure 1a). Interestingly, the protein
expression of 12/15-LO and COX-2 were also clearly higher
in mouse cortical tissue from streptozotocin (STZ)-induced
diabetic mice and diabetic db/db mice relative to control
mice (Figure 1a). Figure 1b shows COX-2 mRNA expression
was increased in glomeruli from diabetic wild-type (WT) and
12/15-LO knock-out (LOKO) mice compared with corres-
ponding controls. However, COX-2 mRNA expression was
greater in glomeruli from WT than LOKO mice under both
basal and diabetic conditions as also shown in the bar graph
quantitation in Figure 1b. We also observed that the
glomeruli in diabetic WT mice showed marked mesangial
expansion characterized histologically by increased periodic
acid-Schiff staining and heavy fibronectin staining relative to
normal control mice. However, these abnormalities were
markedly ameliorated in diabetic LOKO mice (data not
shown).
12(S)-HETE induces COX-2 mRNA and protein expression
in RMC
We then tested our hypothesis that 12(S)-HETE can induce
COX-2 expression in MC. We treated RMC with 12(S)-HETE
for various time periods ranging from 1 to 24 h and various
doses (109–106 M) and examined rat COX-2 mRNA and
protein expression by relative reverse transcription-polymer-
ase chain reaction (RT-PCR) and Western blotting, respec-
tively. Results showed that 12(S)-HETE increased COX-2
protein expression in a dose- (peak effect with 107 M, data
not shown) and time-dependent manner with peak effect at
4–6 h (with 107 M HETE, Figure 2a). In order to determine
whether this increase in COX-2 protein was associated with
increase in COX-2 mRNA expression, we performed RT-PCR
with COX-2-specific primers using 18S as internal control.
We observed that 12(S)-HETE can increase COX-2 mRNA
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Figure 1 | 12/15-LO or COX-2 expression in RMC, mouse cortex
and mouse glomeruli. (a) 12/15-LO and COX-2 protein expression
levels were increased in HG (25 mM)-stimulated RMC, and in cortical
tissues from STZ-induced diabetic mice or db/db mice cortex
compared to matched controls, respectively, NG, normal glucose. (b)
Microdissected glomeruli from WT, LOKO, STZ–diabetic WT and
STZ–diabetic LOKO mice were used to assess COX-2 mRNA
expression. COX-2 mRNA expression was increased in diabetic WT
and LOKO mice compared with corresponding controls, whereas
COX-2 mRNA expression levels were greater in WT mice relative to
LOKO mice under basal and diabetic conditions. Data represent
mean7s.e.m. of three independent experiments (*Po0.01 vs WT;
þPo0.01 vs LOKO; #Po0.01 vs WTþ STZ).
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Figure 2 | Effect of 12(S)-HETE on COX-2, COX-1 expression and
PGE2 levels in RMC. (a) COX-2 protein expression was increased in a
time-dependent manner by 12(S)-HETE (107 M) treatment. (b) COX-2
mRNA expression was increased in time-dependent manner in RMC
by 12(S)-HETE (107 M) stimulation. (c) RMC was treated with 12(S)-
HETE (107 M) or 12(R) -HETE (107 M) for 24 h. Both 12(S)- or 12(R)-
HETE had no effects on the levels of the COX-1 mRNA expression. (d)
RMC was treated with 12(S)-HETE (107 M) or 12(R)-HETE (107 M) for
24 h and cell-released PGE2 was measured by enzyme immunoassay.
12(S)-HETE, but not 12(R)-HETE increased PGE2 levels in the super-
natants. Data represent mean7s.e.m. of four independent experi-
ments (*Po0.01 vs Ctrl).
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expression in a time-dependent fashion in RMC (Figure 2b).
12(S)-HETE was also able to enhance COX-2 activity as it
increased levels of the COX-2 product, PGE2, whereas in
contrast a stereoisomer 12(R)-HETE (which is not a 12/15-
LO product) was without any effect (Figure 2d). Further-
more, both 12(S)- or 12(R)-HETE had no effects on the
mRNA levels of the COX-1 isoform (Figure 2c). These results
demonstrate that 12(S)-HETE can specifically increase the
expression of COX-2.
PGE2 induces 12/15-LO product formation and 12/15-LO
expression in RMC
We next examined our hypothesis that the inflammatory
COX-2 product can, in turn, activate the 12/15-LO pathway
in a reciprocal fashion. We first examined whether PGE2 can
induce 12/15-LO mRNA and protein in MC. RMC were
treated with PGE2 for various time periods ranging from 1 to
24 h and various doses (109–106 M) and rat 12/15-LO
mRNA and protein expression were examined by RT-PCR
and Western blotting, respectively. The results showed that
PGE2 can clearly increase 12/15-LO protein expression in a
dose- (data not shown) and time-dependent (Figure 3a)
manner. Similarly, PGE2 could increase 12/15-LO mRNA
expression by 6 h in RMC and this remained elevated for 24 h
(Figure 3b). We next examined whether PGE2 can alter 12/
15-LO activity by examining levels of cell-released 12(S)-
HETE. Figure 3c shows that PGE2 treatment significantly
increased the levels 12(S)-HETE released in the cell super-
natants after 24 h.
COX-2 expression was decreased in mouse mesangial cells
from 12/15-LOKO and increased in a mouse mesangial cell
line stably overexpressing 12/15-LO relative to control
As LO products could increase COX-2 expression, we next
hypothesized that mouse mesangial cells (MMC) derived
from LOKO mice would have lower levels of COX-2 than
those from control WT mice. Figure 4a shows that the
expression levels of COX-2 protein were lower in MMC from
LOKO mice relative to those from WT. Figure 4b shows that
COX-2 mRNA levels were also significantly lower in these
MMC derived from LOKO mice. Levels of COX-2 transcript
were quantitated as the ratio of density of the COX-2 band to
the 18S band and depicted by the bar graph in Figure 4b.
As 12(S)-HETE increased COX-2 expression in MC and
COX-2 expression was lower in MMC and glomeruli from
LOKO mice, we hypothesized that, reciprocally, COX-2
expression would be greater in MC that overexpress 12/15-
LO. MMC stably overexpressing 12/15-LO had greater levels
of mouse COX-2 protein (Figure 5a) and mRNA (Figure 5b)
expression relative to the mock-transfected pcDNA cells. Bar
graph in Figure 5b shows quantitation of COX-2 transcript
levels as the ratio of density of the COX-2 band to the 18S
band. These results suggest that COX-2 expression is
induced, at least in part by 12/15-LO pathway in diabetic
conditions.
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Figure 3 | Effect of PGE2 on 12/15-LO expression and 12(S)-HETE
formation in RMC. (a) 12/15-LO protein expression was increased in
a time-dependent manner by PGE2 treatment. (b) 12/15-LO mRNA
expression was increased in a time-dependent manner in RMC by
treatment with PGE2. (c) RMC was treated with PGE2 (10
7
M) for 24 h
and cell-released 12(S)-HETE was measured by radioimmunoassay.
PGE2 significantly increased 12(S)-HETE in the supernantants. Data
represent mean7s.e.m. of four independent experiments (*Po0.01
vs Ctrl).
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Figure 4 | COX-2 expression in WT vs 12/15-LOKO MMC. MMC
from WT and 12/15-LOKO mice were used to assess COX-2 mRNA and
protein expression. (a) COX-2 protein expression (b) and mRNA
expression were lower in LOKO relative to WT. Bar graphic
representation shows that COX-2 mRNA is significantly lower in LOKO
vs WT. Data represent mean7s.e.m. of four independent experi-
ments (*Po0.01 vs WT).
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Figure 5 | COX-2 mRNA and protein expression were increased in
MMC cell line stably overexpressing 12/15-LO. 12/15-LO
overexpressing cells (pcDNA/m12/15-LO) and control
mock-transfected cells (pcDNA) were used to assess COX-2 mRNA
and protein expression. (a) COX-2 protein expression was higher
in 12/15-LO-overexpressing cells relative to mock-transfected cells.
(b) Scanned gel and graphic representation showing increased
COX-2 mRNA in 12/15-LO overexpressing cells vs mock-transfected
cells. Data represent mean7s.e.m. of four independent
experiments (*Po0.01 vs pcDNA).
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COX-2 expression was reduced by 12/15-LO short hairpin
RNA, while 12/15-LO expression was reduced by COX-2 short
hairpin RNA
We then evaluated an additional loss of function approach
with short hairpin RNAs (shRNAs) to further establish the
cross-regulation of the 12/15-LO and COX-2 pathways. RMC
were transfected with shRNAs targeting rat 12/15-LO or
COX-2 as described in the Materials and methods section.
After 48 h, the cells were placed in a fresh medium containing
G418 to collect G418-resistant colonies. We confirmed that
12/15-LO shRNA and COX-2 shRNA can effectively knock-
down the 12/15-LO and COX-2 protein expression, respec-
tively, in RMC. Results shown in Figure 6a indicate that the
12/15-LO shRNA reduced levels of 12/15-LO in RMC as
anticipated, but interestingly, the COX-2 shRNA clearly
reduced the levels of 12/15-LO protein relative to control.
This was not a nonspecific effect as a control scrambled
shRNA was not effective under these conditions. Interest-
ingly, Figure 6b shows that similarly, COX-2 protein levels
were decreased not only by the COX-2 shRNA, but also by
the 12/15-LO shRNA. These results suggest that COX-2
expression is mediated, at least in part, by 12/15-LO pathway
products and vice versa.
Role of mitogen-activated protein kinase activation in
mediating 12(S)-HETE and PGE2 effects in RMC
We next examined the role of specific common signal
transduction mechanisms by which 12(S)-HETE and PGE2
exert their effects and potentially mediate a cross-talk. We
therefore examined the activation of key growth- and stress-
related mitogen-activated protein kinases (MAPKs). Serum-
depleted RMC were treated with 12(S)-HETE (107 M) or
PGE2 (10
7
M) for various time periods and MAPK activation
determined by Western blotting. As shown in Figure 7a, a
marked increase in p38 MAPK activation could be seen
within 1 h after stimulation with 12(S)-HETE and remained
elevated until 24 h. However, 12(S)-HETE did not signifi-
cantly activate extracellular signal-regulated kinase (ERK) 1/2
MAPK. As shown in Figure 8a, PGE2 in turn could increase
both p38 MAPK and ERK1/2 activation 1–24 h. Given that
12(S)-HETE increased both p38 MAPK phosphorylation and
COX-2 expression, we postulated that the p38 MAPK
pathway was involved in mediating 12(S)-HETE-induced
COX-2 expression. Serum-depleted RMC were pretreated
with the p38 MAPK inhibitor SB202190 (106 M) for 30 min
and then stimulated with 12(S)-HETE for 24 h. SB202190
could inhibit the activation of p38 MAPK by 12(S)-HETE as
anticipated (data not shown). In the presence of SB202190,
12(S)-HETE-induced increase in COX-2 was clearly attenu-
ated (Figure 7b). Next, we evaluated whether the p38 MAPK
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Figure 6 | Effects of 12/15-LO and COX-2 shRNAs on 12/15-LO and
COX-2 expression in RMC. (a) 12/15-LO shRNA and (b) COX-2 shRNA
attenuated 12/15-LO and COX-2 expression levels, respectively.
(a) 12/15-LO shRNA also markedly decreased COX-2 protein
expression in RMC relative to control, whereas (b) COX-2 shRNA
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Figure 7 | Effect of 12(S)-HETE on MAPK activation and of
p38MAPK inhibitor on 12(S)-HETE-induced COX-2 expression in
RMC. (a) Quiescent RMC were treated in serum-free medium with
12(S)-HETE for various time periods and p38 MAPK and ERK1/2
phosphorylation was determined by Western blotting with phospho-
specfic antibodies. Blots were stripped and reprobed using total p38
and ERK1/2 antibodies as internal controls. (b) Quiescent RMC were
pretreated with p38 MAPK inhibitor SB202190 for 30 min and then
stimulated with 12(S)-HETE for 24 h. COX-2 expression was deter-
mined by Western blot. Data represent mean7s.e.m. of four
independent experiments (*Po0.01 vs untreated Ctrl; þPo0.01 vs
SB202190; #Po0.01 vs 12(S)-HETE).
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Figure 8 | Effect of PGE2 on MAPK activation and of MAPK
inhibitors on PGE2-induced 12/15-LO expression in RMC.
(a) Quiescent RMC were treated in serum-free medium with PGE2 for
various time periods and p38 and ERK1/2 MAPK phosphorylation was
determined by Western blotting with phospho-specfic antibodies.
Blots were stripped and reprobed using total p38 and ERK1/2
antibodies as internal controls. (b) Quiescent RMC were pretreated
with p38 MAPK inhibitor SB202190 or ERK1/2 inhibitor PD98059 for
30 min and then stimulated with PGE2 for 24 h. 12/15-LO expression
was determined by Western blot. Data represent mean7s.e.m. of
four independent experiments (*Po0.01 vs untreated Ctrl; þPo0.01
vs SB202190 or PD98059; #Po0.01 vs PGE2).
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and ERK1/2 pathways were involved in mediating PGE2-
induced 12/15-LO expression. In the presence of SB202190
(106 M) or the ERK1/2 pathway inhibitor PD98059 (106 M),
PGE2-induced 12/15-LO expression was markedly attenuated
(Figure 8b). These results support the operation of a p38
MAPK-dependent cross-talk between the two pathways.
DISCUSSION
Evidence suggest that 12/15-LO and COX-2 are involved in
the pathogenesis of DN.8,16,18–22,24 In support of this, in this
study we found that 12/15-LO and COX-2 expression levels
were increased in MC under high glucose conditions and in
vivo in renal cortical tissues obtained from mouse models of
type I and type II diabetes. Previous studies showed that
urinary 12(S)-HETE and PGE2 were increased in diabetic
mice and diabetic patients, suggesting a renal origin.14–16,20,30
Our current study illustrates the operation of a cross-talk
between these two eicosanoid metabolism pathways.
Many of the actions of 12/15-LO on renal cells resemble
those of high ambient glucose and are reminiscent of the
diabetic changes seen in the kidney.9–11,13 We recently
demonstrated that the 12/15-LO pathway of arachidonate
metabolism was enhanced in experimental DN in rats and
correlated with the expression of the extracellular matrix
protein fibronectin.8,20 Furthermore, LO products such as
12(S)-HETE could directly increase cellular hypertrophy and
production of extracellular matrix and profibrotic proteins,
such as fibronectin, collagen and transforming growth
factor–b in RMC.9,10,13 Factors such as angiotensin II and
HG that are relevant to the pathogenesis of diabetes could
directly increase the activity and expression of 12/15-LO in
MC.8–10 Furthermore, cellular growth and growth factor
effects were greatly attenuated in MC derived from LOKO
mice.9 Our unpublished data also indicate that glomerular
extracellular matrix expansion was ameliorated in LOKO
diabetic mice relative to WT diabetic mice. Consistent with
this data, recently we demonstrated that the 12/15-LO shRNA
reduced fibronectin, collagen and transforming growth
factor-b expression in RMC.13 We now demonstrate another
novel action of the LO pathway in the kidney.
COX-2 is known to be an important physiological
mediator of kidney function and COX-2-derived products
also have several beneficial renal effects by mediating
processes such as medullary blood flow and renal salt
handling.27–29 In addition to the physiological role of COX-
2 in the kidney, increased renal cortical COX-2 expression has
been observed in experimental models associated with altered
renal hemodynamics and progressive renal injury, and long-
term treatment with selective COX-2 inhibitors or PGE2
receptor antagonists ameliorate functional and structural
renal damage in these conditions.16,18,19,21,22,25 COX-2-
derived prostanoids may be essential for afferent arteriolar
vasodilation, which can contribute to glomerular hyperfiltra-
tion related to progression of DN.6,15,17 However, long-term
use of COX-2-specific inhibitors have been associated with
multiple problems as they can interfere with the beneficial
effects of other key protective COX-2 metabolites such as
prostacyclin.31,32
Although 12/15-LO and COX-2 and their products have
been implicated in the pathogenesis of renal diseases such as
DN, the existence of a potential cross-talk between them in
MC has not been previously reported. Recently, it was
demonstrated that 12(S)-HETE can activate COX-2 expres-
sion in pancreatic b-cells.33 In the current study, we observed
for the first time that the 12-LO product, 12(S)-HETE can
increase COX-2 mRNA and protein expression in MC in a
time- and dose-dependent fashion. Levels of the proinflam-
matory COX-2 product PGE2 were also significantly
increased. These effects were specific as 12(S)-HETE did
not increase expression of the COX-1 isoform, and
furthermore, 12(R)-HETE, which is not an LO product, did
not significantly alter COX-2 expression. We also demon-
strated for the first time that the COX-2 product PGE2 could
reciprocally increase the expression of 12/15-LO mRNA and
protein expression and also increased levels of 12(S)-HETE
released by MC. This indicates that oxidized bioactive lipids
such as those generated by the COX-2 and 12/15-LO
pathways can cross-activate the corresponding enzymes and
thereby greatly augment the processes involved in the
progression of DN.
In order to further evaluate this cross-talk, we made MC
deficient in 12/15-LO or COX-2 by using shRNAs targeted to
knockdown these genes. RNA interference mediated by
siRNAs is a powerful tool to inhibit gene expression and
rapidly investigate gene-specific functions.34–36. In this study,
we expressed U6-promoter-driven shRNAs to effectively
suppress rat leukocyte-type 12/15-LO and COX-2 gene
expression. These shRNAs also expressed green fluorescent
protein for tracking transfection efficiency and cellular
localization.37 We observed that shRNAs targeting COX-2
and 12/15-LO mRNAs, as expected, caused a profound
repression of COX-2 and 12/15-LO expression, respectively,
in MC, but control scrambled vectors were not effective.
However, interestingly, we noted that COX-2 expression was
also reduced by the 12/15-LO shRNA whereas 12/15-LO also
was attenuated by the COX-2 shRNA. Furthermore, COX-2
expression was also reduced in MMC from LOKO mice and
reciprocally increased in an MMC cell line stably over-
expressing 12/15-LO. These results suggest that 12/15-LO
pathway may contribute to renal dysfunction via COX-2
pathway and vice versa.
These data strongly support our hypothesis that there is an
interplay and cross-talk amplification loop between the 12/
15-LO and COX-2 pathways in MC, and this may contribute
to the development or progression of DN. It is likely that,
under diabetic conditions, increased 12/15-LO product
induces COX-2 activation and COX-2 metabolites may
contribute to the progression of DN via hemodynamic
effects. Similarly, increased 12/15-LO products by COX-2-
derived metabolites play a pivotal role especially in cellular
hypertrophy and extracellular matrix accumulation. How-
ever, the signaling pathways by which 12/15-LO and COX-2
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products interact with the actions of each other are not very
clear. Recent studies indicated that MAPKs are involved in
the expression of 12/15-LO and COX-210,23,29,38–42 and our
previous study demonstrated that MAPK and 12/15-LO
pathways can interact in mediating growth and matrix
protein expression in MC.10 In order to evaluate the 12/15-
LO and COX-2 interactive signaling mechanisms, we
examined the effect of 12(S)-HETE and PGE2 on MAPK
activation. 12(S)-HETE could directly activate p38, but not
ERK1/2 MAPK, whereas PGE2 could activate both p38 and
ERK1/2 MAPKs. Moreover, a specific chemical inhibitor of
p38 MAPK, SB202190, blocked 12(S)-HETE-induced COX-2
expression. The ERK1/2 pathway specific inhibitor PD98059
and p38 MAPK inhibitor SB202190 both inhibited PGE2-
induced 12/15-LO expression. Thus, MAPKs appear to play
important roles in mediating the cross-talk between COX-2
and 12/15-LO. Further studies are needed to clarify the role
of other mediators in the interaction between 12/15-LO and
COX-2 pathways. Studies are also needed to examine whether
12-HETE- and PGE2-mediated regulation of COX-2 and 12/
15-LO, respectively, occurs at the level of transcription or
message stabilization, and if so, the specific molecular
mechanisms involved. The potential roles of other COX-2
and LO metabolites also need to be investigated.
In summary, our present study provides the first evidence
of an interaction and cross-talk between the 12/15-LO and
COX-2 pathway in renal cells and suggests that this
interaction may amplify the progression of various renal
diseases including DN.
MATERIALS AND METHODS
Materials
12(S)-HETE and its stereoisomer 12(R)-HETE were from Biomol
(Plymouth Meeting, PA, USA); PGE2 was from Sigma (St Louis,
MO, USA); RPMI 1640 medium and fetal bovine serum were from
Gibco BRL (Grand Island, NY, USA); COX-2 antibody was from
Cayman Chemical Company (Ann Arbor, MI, USA). We also used a
12/15-LO peptide antibody as described previously.8 b-Actin
antibody was from Sigma; horseradish peroxidase-conjugated
secondary antibody was from Cell Signaling (Beverly, MA, USA);
the chemiluminescence reagent Supersignal was from Pierce (Rock-
ford, IL, USA); PGE2 enzyme immunoassay kits were obtained from
Cayman Chemical Company; Relative multiplex RT-PCR kits and
primers for Quantum RNA 18S internal standards were from
Ambion Inc. (Austin, TX, USA); Lipofectamine 2000 transfection
reagent was from Invitrogen (Carlsbad, CA, USA) and RNA-STAT
60 reagent was from Tel-Test (Friendswood, TX, USA).
Cell culture
Primary cultures of RMC from Sprague–Dawley rats were obtained
by enzymatic digestion as described previously8,9 and cultured in
RPMI 1640 supplemented with 10% fetal bovine serum at 371C in
5% CO2. Cells between 5 and 8 passages were used for all studies.
Primary cultures of mouse MC from genetic control (C57BL/6, WT,
USA), the leukocyte LOKO mice (Strain name: B6.129S2-
Alox15tm1Fun, Stock Number 002778) (Jackson Laboratories, Bar
Harbor, ME, USA) were obtained by modified enzymatic digestion
as described previously.9,13
Animals
All animal studies were conducted under a protocol approved by the
Institutional Research Animal Care Committee. The animals were
housed in a temperature-controlled room and were given free access
to water and standard laboratory chow. C57BL/6 mice and LOKO
mice received 50 mg/kg of STZ intraperitoneally on 5 consecutive
days. Blood glucoses were measured to confirm the development of
diabetes (fasting glucose 4300 mg/dl). Mice injected with diluent
served as controls. All mice were killed after 16 weeks. Ten-week old
male C57BLKsJ-db/db mice and their age-matched non-diabetic db/
m littermates were used in this study.
Glomerular microdissection
For experiments using glomeruli, six male WT and six male 12/15-
LOKO C57BL/6 mice were used. Glomerular microdissection was
performed as previously described.8
Construction of shRNA and transfection
We used RNA interference initiated by expressed U6-promoter-
driven shRNAs to effectively suppress the levels of rat leukocyte-type
12/15-LO and COX-2 genes. Design and construction of the shRNA
and control scrambled vectors, transfection methods and selection
of transformants were performed as described previously.37 Stable
mouse 12/15-LO overexpression was performed in an immortalized
MMC cell line (generous gift from Dr K Sharma, Thomas Jefferson
University, Philadelphia, PA, USA). To generate these cells over-
expressing mouse leukocyte-type 12/15-LO, the MMC cell line was
transfected as described13 with either mouse leukocyte 12/15-LO
cDNA in pcDNA3.1 vector (generous gift from Dr Colin Funk,
University of Pennsylvania, Philadelphia, PA, USA) or control
pcDNA3.1 vector.
Reverse transcription-polymerase chain reaction
Total RNA was isolated using RNA-STAT 60 reagent according to the
manufacturer’s instructions. cDNA was synthesized with 1 mg of
RNA using murine leukemia virus reverse transcriptase and random
hexamers. Primers for the 18S ribosomal RNA (489 or 324 bp) were
included in each reaction as an internal control. RNA was similarly
reverse transcribed. The RT-PCR products were separated by
electrophoresis and DNA band intensities in agarose gels were
quantitated with Quantitation One software (Bio-Rad Laboratories,
Hercules, CA, USA). The primers used are summarized in Table 1.
Western blot analysis
Cells and cortex were lysed in sodium dodecyl sulfate sample buffer
(2% sodium dodecyl sulfate, 10 mM Tris-HCl, pH 6.8, 10% (vol/vol)
glycerol) and equal amounts of proteins from various treatments
were subjected to immunoblotting with the indicated antibodies
as described.10 Antibodies used were: COX-2 (1:1000), 12/15-LO
(1:500), phospho-p38 MAPK (1:1000), p38 MAPK (1:1000),
phospho-ERK1/2 (1:1000), ERK1/2 (1:1000), and b-actin (1:5000).
Immunoblots were scanned using GS-800 densitometer and protein
bands were quantitated with Quantitation One software (Bio-Rad
Laboratories, Hercules, CA, USA).
12(S)-HETE assay and PGE2 assay
Serum-depleted RMC were treated with PGE2 for 24 h. At the end of
the incubation period, the culture dishes were placed on ice, the
supernatants aspirated and saved at 701C. The HETEs in
the supernatants were extracted and quantitated by a validated
radioimmunoassay.20
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For PGE2 measurements, serum-depleted RMC were treated with
12(R)-HETE or 12(S)- for 24 h. At the end of the incubation period,
the culture dishes were placed on ice, supernatants aspirated and
saved at 701C. PGE2 levels in the supernatants were measured
using a commercial enzyme immunoassay kit according to the
manufacturer’s instructions.
Statistical analysis
Data are expressed as mean7standard error of the mean (s.e.m).
from multiple experiments. Paired Student’s t-tests were used to
compare two groups, or analysis of variance with Tukey’s post-tests
for multiple groups using PRISM software (Graph Pad, San Diego,
CA, USA). Statistical significance was detected at the 0.05 level.
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